Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: Results from the phase 2 CheckMate 9KD trial
Karim Fizazi*, Margitta Retz, Daniel P. Petrylak, Jeffrey C. Goh, Jose Perez-Gracia, Louis Lacombe, Stefanie Zschäbitz, Mauricio Burotto, Hakim Mahammedi, Gwenaelle Gravis, Diogo Assed Bastos, Steven L. McCune, Juan Carlos Vázquez Limón, Edmond M. Kwan, Daniel Castellano, Aude Fléchon, Fred Saad, Marc Oliver Grimm, David R. Shaffer, Andrew J. ArmstrongPrabhu Bhagavatheeswaran, Neha P. Amin, Keziban Ünsal-Kaçmaz, Xuya Wang, Jun Li, Andrea Loehr, Russell K. Pachynski
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
26Scopus
citations
Fingerprint
Dive into the research topics of 'Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: Results from the phase 2 CheckMate 9KD trial'. Together they form a unique fingerprint.